Four 20 Pharma launches its own cannabis brand "420" on the German market

Paderborn (ots)

Four 20 Pharma GmbH, manufacturer, wholesaler and importer of medical cannabis and medical devices, will launch two new cannabis products on the German market under its own brand "420" in the second quarter of 2020. For this purpose, an international supply agreement was concluded with a Canadian producer of medical cannabis, which was audited and reviewed by Four 20 Pharma GmbH. The supplier has EU GMP certification from a German authority, ensuring compliance with the highest quality standards along the entire manufacturing process.

Product quality has top priority

With its two new cannabis products 420 NATURAL 18/1 CA and 420 NATURAL 25/1 CA, Four 20 Pharma GmbH is consistently focusing on consistently high product quality. The new "420" cannabis products are characterized by the fact that they have not undergone any irradiation to be DAB compliant. This means they are 100% natural and have an unaltered terpene profile that would otherwise be affected by irradiation.

About Four 20 Pharma GmbH

Four 20 Pharma GmbH is GDP and GMP certified as a manufacturer, wholesaler and importer of medical cannabis as well as medical devices. The company, based in Paderborn, Germany, was founded in 2018 and holds a narcotics license in accordance with Section 3 of the German Narcotics Act (BtMG) and a pharmaceutical wholesale license in accordance with Section 52a of the German Medicines Act (AMG) for the whole of Europe. In addition, the medical cannabis specialist holds the necessary import licenses for the importation of medical cannabis into Germany, a manufacturing permit, and the necessary, product-specific permit in accordance with § 7 AMG and § 1 AMRadV for the marketing of medicinal products. Four 20 Pharma GmbH is committed to the Association for Cannabis as Medicine (ACM) as a gold sponsor. The company supports physicians, pharmacies, medical institutions and patients as a reliable partner in the field of medical cannabis. For more information, please visit our website at www.420pharma.de.

The new cannabis products are intended for pharmacies and medical facilities and can be pre-ordered from the Four 20 Pharma GmbH online store from April 15, 2020:

420 NATURAL 18/1 CA

THC ca. 18 % | CBD < 1 % | Indica

420 NATURAL 25/1 CA

THC approx. 25 % | CBD < 1 % | Hybrid

The new products are offered in units of 5 g, 15 g, 150 g as well as 400 g. Delivery of 420 NATURAL 18/1 CA is expected to take place in mid-June 2020. 420 NATURAL 25/1 CA is scheduled for the end of July.

"With the launch of our own "420" brand, we clearly stand out from most competitors in the German market. The new, non-irradiated grades round off our existing portfolio and offer patients a high-quality and natural alternative. In the first step, 0.5 tons of medical cannabis will be imported from Canada. This will enable us to noticeably counteract the supply shortage in Germany," Thomas Schatton, Managing Director of Four 20 Pharma GmbH, explains this strategic step.

Outlook: Further cannabis products in planning

The two cannabis products 420 NATURAL 18/1 CA and 420 NATURAL 25/1 CA form the basis and at the same time the starting signal for the development of a comprehensive product portfolio under the 420 brand. According to the current status, a total of up to five additional varieties are in planning. Four 20 Pharma GmbH aims to meet the different needs of patients with regard to THC and CBD content, terpene profiles as well as administration. For this purpose, Four 20 Pharma GmbH is working in cooperation with an Israeli research company in order to be able to offer medical devices for improved and more targeted, dosed intake of the respective active ingredients as an alternative to the classic smoking process in the near future.

Press contact:

Ireneusz Storm
presse@420pharma.eu
+49 5251 39032 - 10

Original content of: Four 20 Pharma GmbH, transmitted by news aktuell